Programmed Cell Death 4 and heart protection during doxorubicin treatment
Official title: Programmed Cell Death 4 in Doxorubicin-Induced Cardiotoxicity
Funded at Mayo Clinic Arizona · NIH-11395225 · Data updated 2026-11-12
A研究 grant looking at how a heart-protective gene called PDCD4 helps prevent heart damage in children treated with doxorubicin chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | August 18, 2025 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $648,757 |
| NIH project number | 5R01HL180393-02 |
| Project ID | NIH-11395225 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children and young survivors who have received or may receive anthracycline chemotherapy.
✕Less likely to help
Patients not exposed to doxorubicin or without risk of anthracycline-related cardiotoxicity.
What this research studies
This project uses a juvenile mouse model to study how the PDCD4 gene influences heart cells after exposure to doxorubicin, a common chemotherapy drug. The researchers will manipulate PDCD4 levels and observe effects on heart cell death and signaling pathways like STAT3 to understand why some patients develop long-term heart problems after treatment. The goal is to uncover mechanisms that could lead to new therapies that protect the heart without reducing chemotherapy effectiveness. If successful, these findings could guide safer cancer treatment strategies for children and cancer survivors. The work combines animal studies with molecular analyses to explore potential protective targets in the heart.
Why it matters
Potential benefit: Could lead to new strategies to prevent or lessen heart damage in children receiving doxorubicin.
How similar studies have gone: Preliminary data suggest PDCD4 influences heart cell survival during doxorubicin exposure, but translation to therapy is still exploratory.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Zhu, Wuqiang — Mayo Clinic Arizona
- Study coordinator: Zhu, Wuqiang
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.